David E. Hamaoui

Array ( [id] => 15740641 [patent_doc_number] => 20200109208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-09 [patent_title] => DESIGN OF THERAPEUTIC IMMUNOGLOBULIN G4 FOR IMPROVED BIOANALYTICAL AND BIOPROCESSING PROPERTIES [patent_app_type] => utility [patent_app_number] => 16/471708 [patent_app_country] => US [patent_app_date] => 2017-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13424 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16471708 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15147861 [patent_doc_number] => 20190352408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/471485 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19670 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16471485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13507813 [patent_doc_number] => 20180305449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => VEGF/DLL4 Binding Agents and Uses Thereof [patent_app_type] => utility [patent_app_number] => 15/847335 [patent_app_country] => US [patent_app_date] => 2017-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45902 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15847335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18620432 [patent_doc_number] => 11753460 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-12 [patent_title] => Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo [patent_app_type] => utility [patent_app_number] => 16/467013 [patent_app_country] => US [patent_app_date] => 2017-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 24000 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16467013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13397559 [patent_doc_number] => 20180250322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => ANTIBODIES WHICH BIND TYPE I CANNABINOID RECEPTOR/ANGIOTENSIS II RECEPTOR HETEROMERS [patent_app_type] => utility [patent_app_number] => 15/839236 [patent_app_country] => US [patent_app_date] => 2017-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15839236 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14899791 [patent_doc_number] => 20190293661 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => METHOD OF PREDICTING RESPONSIVENESS OF WET AMD PATIENT TO ANTI-VEGF THERAPY [patent_app_type] => utility [patent_app_number] => 16/465703 [patent_app_country] => US [patent_app_date] => 2017-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6388 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13507801 [patent_doc_number] => 20180305443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => Methods of Treating Inflammatory Pain [patent_app_type] => utility [patent_app_number] => 15/819868 [patent_app_country] => US [patent_app_date] => 2017-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13545 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15819868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17178375 [patent_doc_number] => 11155610 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-26 [patent_title] => Dual PDGF/VEGF antagonists [patent_app_type] => utility [patent_app_number] => 15/820325 [patent_app_country] => US [patent_app_date] => 2017-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 61 [patent_no_of_words] => 39854 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15820325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14926327 [patent_doc_number] => 20190298801 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => AFLIBERCEPT FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/462527 [patent_app_country] => US [patent_app_date] => 2017-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21686 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16462527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16841726 [patent_doc_number] => 11013785 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-25 [patent_title] => Activin receptor type IIA variants and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/348987 [patent_app_country] => US [patent_app_date] => 2017-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 20 [patent_no_of_words] => 22807 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348987 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12217547 [patent_doc_number] => 20180055907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF CANCER AND METHODS OF SELECTION THEREOF' [patent_app_type] => utility [patent_app_number] => 15/803790 [patent_app_country] => US [patent_app_date] => 2017-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 20566 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15803790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12233187 [patent_doc_number] => 20180066050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-08 [patent_title] => 'USE OF IL-31 MONOCLONAL ANTIBODIES FOR ANTAGONIZING SIGNAL TRANSDUCTION IN DORSAL ROOT GANGLION CELLS' [patent_app_type] => utility [patent_app_number] => 15/800980 [patent_app_country] => US [patent_app_date] => 2017-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16186 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15800980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185490 [patent_doc_number] => 20180044426 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'USE OF IL-31RA MONOCLONAL ANTIBODIES FOR ANTAGONIZING SIGNAL TRANSDUCTION IN DORSAL ROOT GANGLION CELLS' [patent_app_type] => utility [patent_app_number] => 15/799445 [patent_app_country] => US [patent_app_date] => 2017-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16899 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15799445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15524917 [patent_doc_number] => 20200054764 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => MEDICAL USE OF ANTI-C MET ANTIBODY-CYTOTOXIC DRUG CONJUGATE [patent_app_type] => utility [patent_app_number] => 16/340258 [patent_app_country] => US [patent_app_date] => 2017-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16340258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16499873 [patent_doc_number] => 10865248 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-15 [patent_title] => Antigen binding complex having agonistic activity and methods of use [patent_app_type] => utility [patent_app_number] => 15/725208 [patent_app_country] => US [patent_app_date] => 2017-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 31 [patent_no_of_words] => 70933 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15725208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16735678 [patent_doc_number] => 10961314 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-30 [patent_title] => Liquid pharmaceutical composition comprising an anti-IL-6 receptor antibody [patent_app_type] => utility [patent_app_number] => 16/334310 [patent_app_country] => US [patent_app_date] => 2017-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 9260 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16334310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15083605 [patent_doc_number] => 20190336613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => COMPOSITIONS TO TREAT ULTRAVIOLET (UV)-INDUCED SKIN INJURY [patent_app_type] => utility [patent_app_number] => 16/335523 [patent_app_country] => US [patent_app_date] => 2017-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4293 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383737 [patent_doc_number] => 20180243410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => Methods Of Treatment Of Keloid Using An Anti-VEGF Agent [patent_app_type] => utility [patent_app_number] => 15/700992 [patent_app_country] => US [patent_app_date] => 2017-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8621 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15700992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12283321 [patent_doc_number] => 09931421 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-03 [patent_title] => Methods of delivering DLL3 antibody drug conjugates [patent_app_type] => utility [patent_app_number] => 15/694627 [patent_app_country] => US [patent_app_date] => 2017-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 65 [patent_no_of_words] => 68039 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 351 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15694627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12137095 [patent_doc_number] => 20180015178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-18 [patent_title] => 'ANTI-DLL3 ANTIBODY DRUG CONJUGATES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/694629 [patent_app_country] => US [patent_app_date] => 2017-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 72452 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15694629 [rel_patent_id] =>[rel_patent_doc_number] =>)